



SynBalance® SmilinGut

**Bring back
your daily balance**

Gastrointestinal



- › **Probiotic complex for gastro-intestinal health:**
L. plantarum - PBS067
L. rhamnosus - LRH020
B. lactis - BL050
- › **Provides a natural way to support digestive health**
- › **Promotes the balance of a healthy gut microbiota**
- › **Typical dosage: 6B CFU/day (2B CFU/strain)**
- › **Minimum 10 days treatment**
- › **Customized concentration and full service solution available**





✓ In-vitro pathogens inhibition, antiox & anti-inflammatory activity⁽¹⁾

• Inhibition of different pathogens, involved in enteric infections, by probiotics surnatants. Competition is evaluated through overlay assay measured by inhibition halo. Treatment model is mediated by metabolites (SCFA and bacteriocins).


▶ *In-vitro*, SynBalance® SmilinGut strains provide a wide protection from enteric pathogens and support immune functions.

	Acidic metabolites mediated inhibition			Competitive inhibition			HT-29	LP-PBS067	LRh-LRH020	BL-BL050	SmilinGut	SmilinGut (Balb 3T3)
	<i>E. coli</i>	<i>E. faecalis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>E. faecalis</i>	<i>S. aureus</i>	TNF-α					
LP- PBS067	**	*	**	**	**	**		**	**	**	**	***
LRh - LRH020	*	//	//	**	**	**		*	**	*	**	***
BL - BL050	**	//	//	**	**	*		*	*	*	*	ND
SmilinGut	***	ND	ND	**	ND	ND		**	**	*	**	***

*** synergic effect ** strong effect * significant effect
// no effect ND not determined


✓ Clinical improvement of IBS-C like symptoms⁽²⁾

• Protocol: oral intake (60 days), 50 subjects group, randomized, double blind, placebo controlled. Method: collection of stools & questionnaire. End-point: GI-tract colonization, clinical evaluation of symptoms. Analytical technique: Real time - PCR / Analysis performed at T0, T10, T30, T60, T90 (30dd wash out). VAS score based on symptoms scale: abdominal swelling, bloating / flatulence, pain / discomfort, constipation.



- ▶ Self-assessment: subjects declaring over 30% improvement of symptoms.
- ▶ Good results for all indicators already after 10 days.
- ▶ Long-term effect after the end of treatment consistently lower than placebo and basal value (p<0.001).

✓ Clinical evidence of GI colonization⁽²⁾



- ▶ Selective, consistent and significant improvement of administered strains in the study group (p<0.01).
- ▶ No significant increase in the placebo group for any specie.

(1) I. Presti, G. D'Orazio, M. Labra, et al., "Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect," Applied Microbiology and Biotechnology, vol. 99, no. 13, pp. 5613-5626, 2015

(2) V. Mezzasalma et al., "A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation" BioMed Research International, 2016

DISCLAIMER: The statements made in this document have not been evaluated by EFSA, FDA or any local authority. The ingredients presented here are not intended to diagnose, treat, cure or prevent any disease. This document is reserved for the operators and technicians, this information are only for business-to-business purposes, not for consumers. Please refer to local authority for further information.